Life sciences & health care in Belgium
Patients are at the centre of the Life Sciences & Health Care universe; however, the number of stakeholders and interactions is particularly large and diverse, which multiplies the challenges.
Belgium is a“Pharma-Valley” in Europe!
- In 2009, total market value (ex-factory price) in Belgium stood up to 4,4 Billion EUR, i.e. 1.3% of the national GDP. The total export amounts to 37.5 Billion EUR, or 14% of the total Belgian exportations
- Belgium has a strong Health Care system with following attributes:
- Freedom of choice for patients (a patient can choose to go to a GP or directly to a specialist) with a high density of Health Care professionals and hospital beds and virtually no waiting lists.
- Strong government interference through the National Institute for Sickness and Invalidity Insurance, commonly known as INAMI/RIZIV
- Independent medical practice based on fee-for-service reimbursement, managed by non-profit statutory sickness funds known as mutualités/mutualiteiten
- R&D spending from the total Pharma industry reached 1.8 Billion EUR in 2009, or 24,3% of the private sector spending, and with more than 4700 researchers in 2007 represents 21,5% of the total R&D employment in the private sector.
Source: Witboek Life Sciences Industry Vlaanderen, Pharma.be
Material on this website is © 2013 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.